Showing results (251-260 of 392) with videos related to
Sort By:
Pageof 40
Blood|January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcomeLorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.Blood|December 1, 2005
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational statusMia Thorsélius, Alexander Kröber, Fiona Murray, et al.Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.Blood|October 11, 2012
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsJennifer Edelmann, Karlheinz Holzmann, Florian Miller, et al.Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.Pageof 40